Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
CHICAGO ? Adding a premeal short-acting glucagonlike peptide?1 agonist is an attractive alternative to add-on prandial insulin when intensification of basal insulin no longer controls type 2 diabetes, according to the findings of the 4B trial.
"Addition of prandial insulin has been the gold standard. But we know that that is often associated with a high risk of hypoglycemia, weight gain, and low patient acceptance, so we need alternative treatment approaches," principal investigator Dr. Michaela Diamant said, in explaining the study rationale at the annual scientific sessions of the American Diabetes Association.
http://www.clinicalendocrinologynew...iabetes/10a595fe127aacd7114208f004799486.html
"Addition of prandial insulin has been the gold standard. But we know that that is often associated with a high risk of hypoglycemia, weight gain, and low patient acceptance, so we need alternative treatment approaches," principal investigator Dr. Michaela Diamant said, in explaining the study rationale at the annual scientific sessions of the American Diabetes Association.
http://www.clinicalendocrinologynew...iabetes/10a595fe127aacd7114208f004799486.html